On Wednesday, Goldman Sachs analyst Salveen Richter downgraded Moderna (NASDAQ:MRNA) stock from Buy to Neutral, significantly reducing the price target to $51 from the previous $99. Trading at $44 ...

Goldman Sachs updated its Sharpe Ratio basket, a list of 50 stocks with the highest expected risk-adjusted returns in the ...

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to ...

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy.

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (WBAG:MRNA) from Buy to Neutral. There are 1,449 funds or institutions reporting positions in Moderna ...

The S&P 500 and Nasdaq added to their all-time highs at midday as investors anticipated more U.S. trade agreements ahead.

Goldman Sachs analyst Salveen Richter downgrades Moderna from Buy to Neutral and lowers the price target from $99 to $51. The analyst expects Moderna to report product revenue at the low end of ...

We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this piece, we will look at where ranks on the list. With the 2024 US ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (BIT:1MRNA) from Buy to Neutral. As of January 28, 2025, the average one-year price target for Moderna ...

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna shares (MRNA) fell 2% in ...

Moderna's recent forecast for fiscal year 2025 respiratory vaccine business revenue is set between $1.5 billion and $2.5 billion, with Goldman Sachs estimating the lower end of this range.